Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B Study of ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

NCT03254732 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT03254732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03254732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B Study of ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
Lead sponsor
Polaris Group
Phase
Phase 1
Overall status
Terminated
Start date
July 14, 2017
Completion date
February 25, 2020
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancers